Browsing Tag
Hengrui Pharma
2 posts
Hengrui lands $2.6bn Novo Nordisk deal for experimental weekly oral obesity drug
Novo Nordisk licenses Hengrui’s weekly oral GLP-1/GIP drug HRS-1596 for up to $2.6 billion as obesity competition intensifies.
Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up
Braveheart Bio is seeking up to $318.8 million in its Nasdaq IPO, but investors must decide whether its cardiac myosin inhibitor can compete in an increasingly crowded hypertrophic cardiomyopathy market.